Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms arising from neuroendocrine system cells. These tumours can occur throughout the body but are most commonly found in the gastrointestinal tract, pancreas, and lungs. The diagnosis and management of NETs rely heavily on imaging, which is crucial for accurate tumour localisation, staging, and monitoring treatment response.
Recent advances in imaging technologies have significantly improved the detection and characterisation of NETs. Conventional imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) remain staples in the evaluation of these tumours. CT provides excellent anatomical detail, which is essential for surgical planning and detecting metastases. MRI is preferred for its superior contrast resolution, which is particularly beneficial for identifying liver metastases and for imaging pancreatic NETs.
However, the cornerstone of NET imaging is nuclear medicine techniques, specifically positron emission tomography (PET) combined with CT (PET/CT). The most commonly used radiotracer, 68-Gallium-DOTATATE, binds to somatostatin receptors abundantly expressed on many NET cells’ surfaces. This method offers high sensitivity and specificity and enables the assessment of receptor status, which is crucial for planning receptor-targeted therapies.
Another promising advancement is the introduction of 18F-FDG PET/CT, which is particularly useful in imaging high-grade NETs that do not express somatostatin receptors. This technique assesses tumours’ metabolic activity, providing vital prognostic information and aiding in the differentiation of tumour grades.
As imaging technology evolves, the integration of artificial intelligence (AI) is poised to enhance the precision of NET diagnostics further. AI algorithms can help quantify tumour burden and predict treatment response, thereby personalising patient management. These technological advancements underscore the dynamic nature of neuroendocrine tumour imaging and its pivotal role in the comprehensive care of patients with NETs.
You are here:
home »
By | 10 minutes of readingLead-212 VMT-α-NET offers advanced targeted therapy for neuroendocrine tumours by harnessing precise alpha-particle radiation.
By | 13 minutes of readingLead-212 DOTAMTATE targets somatostatin receptors in neuroendocrine tumours, delivering potent alpha-emission therapy with minimal off-target toxicity.
Lead-212 DOTAMTATE: A Novel Alpha-Emitting Therapy for Neuroendocrine Tumours Read Post »
By | 4 minutes of readingLutetium-177 Satoreotide Tetratexan is a radiopharmaceutical targeting somatostatin receptors, providing advanced therapeutic options for neuroendocrine neoplasms effectively.
By | 15 minutes of readingLutetium-177 Oxodotreotide Treatment offers targeted neuroendocrine tumour therapy, improving progression-free survival and patient outcomes significantly.
Neuroendocrine Tumour Therapy with Cutting-Edge Lutetium-177 Oxodotreotide Innovation Read Post »
By | 10 minutes of readingLutetium-177 Ludotadipep targets PSMA with enhanced stability, specificity, and reduced side-effects, revolutionising prostate cancer treatment.
By | 10 minutes of readingLutetium-177 LNC1010, a radiolabelled therapy, targets somatostatin receptors, delivering precise treatment with minimal side effects.
By | 9 minutes of readingLutetium-177 Edotreotide revolutionises neuroendocrine tumour treatment through targeted radioligand therapy, enhancing precision and improving patient outcomes.
By | 10 minutes of readingLutetium-177 DTPA-Omburtamab offers hope in neuroblastoma treatment by precisely targeting B7-H3, delivering localised radiation while sparing healthy tissues.
By | 6 minutes of readingThe study critically evaluates 3D-to-2D knowledge distillation in neuroimaging classification, balancing volumetric insights with computational efficiency for real-world applications.
By | 4 minutes of readingIodine-131 TM601, a synthetic radiolabelled peptide, targets tumour cells expressing Annexin A2, delivering therapeutic radiation and exhibiting anti-angiogenic properties effectively.
Iodine-131 TM601: Targeting Tumours with Radiolabelled Peptides Read Post »
By | 8 minutes of readingIodine-131 Iobenguane revolutionises neuroendocrine tumour management by offering targeted imaging and therapy, significantly improving diagnosis, treatment, and patient outcomes.
By | 10 minutes of readingPeptide Receptor Radionuclide Therapy offers a targeted approach to treating neuroendocrine tumours, improving survival rates and quality of life.
Advances in Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumours Read Post »
By | 4 minutes of readingThe REAL-LU study highlights Lutetium-177 DOTATATE’s real-world effectiveness, safety, and quality-of-life impact in Italian patients with GEP-NETs.
